Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

PubMed  Google Scholar 

Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005–20.

CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

CAS  PubMed  PubMed Central  Google Scholar 

Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603:942–8.

CAS  PubMed  PubMed Central  Google Scholar 

Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78–86.

CAS  PubMed  Google Scholar 

Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34:1448–54.

CAS  PubMed  Google Scholar 

Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018;19:1437–48.

CAS  PubMed  Google Scholar 

Lorenzen S, Thuss-Patience P, Pauligk C, Gökkurt E, Ettrich T, Lordick F, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO. Eur J Cancer. 2022;165:48–57.

CAS  PubMed  Google Scholar 

Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.

CAS  PubMed  PubMed Central  Google Scholar 

Hara H, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Nakatsuka R, et al. Overexpression of glypican-1 implicates poor prognosis and their chemoresistance in oesophageal squamous cell carcinoma. Br J Cancer. 2016;115:66–75.

CAS  PubMed  PubMed Central  Google Scholar 

Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001;108:497–501.

CAS  PubMed  PubMed Central  Google Scholar 

Pan J, Ho M. Role of glypican-1 in regulating multiple cellular signaling pathways. Am J Physiol Cell Physiol. 2021;321:C846–58.

CAS  PubMed  PubMed Central  Google Scholar 

Sparn C, Dimou E, Meyer A, Saleppico R, Wegehingel S, Gerstner M, et al. Glypican-1 drives unconventional secretion of fibroblast growth factor 2. Elife. 2022;11: e75545.

CAS  PubMed  PubMed Central  Google Scholar 

Lu H, Niu F, Liu F, Gao J, Sun Y, Zhao X. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma. Cancer Med. 2017;6:1181–91.

CAS  PubMed  PubMed Central  Google Scholar 

Chen G, Wu H, Zhang L, Wei S. High glypican-1 expression is a prognostic factor for predicting a poor clinical prognosis in patients with hepatocellular carcinoma. Oncol Lett. 2020;20:197.

PubMed  PubMed Central  Google Scholar 

Yokota K, Serada S, Tsujii S, Toya K, Takahashi T, Matsunaga T, et al. Anti-glypican-1 antibody-drug conjugate as potential therapy against tumor cells and tumor vasculature for glypican-1-positive cholangiocarcinoma. Mol Cancer Ther. 2021;20:1713–22.

CAS  PubMed  Google Scholar 

Munekage E, Serada S, Tsujii S, Yokota K, Kiuchi K, Tominaga K, et al. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma. Neoplasia. 2021;23:939–50.

CAS  PubMed  PubMed Central  Google Scholar 

Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016;76:2710–9.

CAS  PubMed  Google Scholar 

Szot C, Saha S, Zhang XM, Zhu Z, Hilton MB, Morris K, et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest. 2018;128:2927–43.

PubMed  PubMed Central  Google Scholar 

Tsujii S, Serada S, Fujimoto M, Uemura S, Namikawa T, Nomura T, et al. Glypican-1 is a novel target for stroma and tumor cell dual-targeting antibody-drug conjugates in pancreatic cancer. Mol Cancer Ther. 2021;20:2495–505.

CAS  PubMed  Google Scholar 

Nishigaki T, Takahashi T, Serada S, Fujimoto M, Ohkawara T, Hara H, et al. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer. Br J Cancer. 2020;122:1333–41.

CAS  PubMed  PubMed Central  Google Scholar 

Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X, et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther. 2015;14:1376–84.

CAS  PubMed  PubMed Central  Google Scholar 

Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538–49.

PubMed  Google Scholar 

Kemi N, Eskuri M, Herva A, Leppänen J, Huhta H, Helminen O, et al. Tumour-stroma ratio and prognosis in gastric adenocarcinoma. Br J Cancer. 2018;119:435–9.

CAS  PubMed  PubMed Central  Google Scholar 

Peng C, Liu J, Yang G, Li Y. The tumor-stromal ratio as a strong prognosticator for advanced gastric cancer patients: proposal of a new TSNM staging system. J Gastroenterol. 2018;53:606–17.

PubMed  Google Scholar 

Uchida S, Serada S, Suzuki Y, Funajima E, Kitakami K, Dobashi K, et al. Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma. Neoplasia. 2024;50: 100982.

CAS  PubMed  PubMed Central  Google Scholar 

Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J, et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun. 2021;12:3528.

CAS  PubMed  PubMed Central  Google Scholar 

Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419–30.

CAS  PubMed  Google Scholar 

Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41:1173–82.

PubMed  Google Scholar 

Xu Y, Wang Y, Gong J, Zhang X, Peng Z, Sheng X, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer. 2021;24:913–25.

CAS  PubMed  PubMed Central  Google Scholar